Ultrapotent, broadly neutralizing and long-acting

anti-SARS-CoV-2 mAbs for the prevention of

COVID-19 infection in immunocompromised patients

MISSION

 

  • SpikImm was founded in 2021 by Truffle Capital and the Institut Pasteur to develop human monoclonal antibodies (mAbs) to prevent COVID-19.
  • SPK001, SpikImm’s lead candidate, originally developed in the laboratory of Humoral Immunology (Institut Pasteur & Inserm) headed by Dr Hugo MOUQUET, has demonstrated a potent and broad neutralization activity in vitro against SARS-CoV-2 and all variants of concern (including Delta and Omicron BA.1 and BA.2), as well as a therapeutic efficacy in vivo in mouse and hamster models.
  • SPK001 is developed as a long-acting antibody with a convenient, intramuscular administration for the prevention of COVID-19 (pre-exposure prophylaxis) in immunocompromised patients unable to mount a protective antibody response after vaccination.
  • SpikImm expects to start clinical trials mid-2022.

TEAM

MANAGEMENT

Antoine Pau, PharmD

Antoine Pau, PharmD

Acting CEO

Dr. Catherine Combot-Plétan

Dr. Catherine Combot-Plétan

Chief Development Officer

Pr. Karine Lacombe

Pr. Karine Lacombe

Chief Medical Officer

Dr. Hélène Sicard

Dr. Hélène Sicard

Preclinical expert

Dr. Jérôme Tiollier

Dr. Jérôme Tiollier

CMC expert

Dr. Didier Haguenauer

Dr. Didier Haguenauer

Head of clinical development

INVENTOR & SCIENTIFIC DIRECTOR

Dr. Hugo Mouquet

Dr. Hugo Mouquet

BOARD OF DIRECTORS

Dr. Philippe Pouletty

Dr. Philippe Pouletty

Chairman

Pr. Jorge Kalil

Pr. Jorge Kalil

Pr. Hartmut J. Ehrlich

Pr. Hartmut J. Ehrlich

SCIENCE

Potent human broadly SARS-CoV-2–neutralizing IgA and IgG antibodies effective against Omicron BA.1 and BA.2Goes Here

MEDIA

PR April 2022

Press release April 2022

france 2030

Press release France 2030

Pasteur.fr

Businesswire.com

Nature.com